SHORT COMMUNICATION

Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: A prospective cohort study in Lesotho (DO-REAL study)

Jennifer A. Brown[1,2,3] | Bienvenu L. Nsakala[4] | Kuena Mokhele[4] | Itumeleng Rakuoane[4] | Josephine Muhairwe[4] | Lorena Urda[2,3] | Alain Amstutz[1,3,5] | Nadine Tschumi[1,3] | Thomas Klimkait[2,3] | Niklaus D. Labhardt[1,3,5]

[1]Clinical Research Unit, Department of Medicine, Swiss Tropical and Public Health Institute, Basel, Switzerland

[2]Molecular Virology Group, Department of Biomedicine, University of Basel, Basel, Switzerland

[3]University of Basel, Basel, Switzerland

[4]SolidarMed, Partnerships for Health, Maseru, Lesotho

[5]Department of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland

Correspondence
Niklaus D. Labhardt, Socinstrasse 57, 4051 Basel, Switzerland.
Email: n.labhardt@unibas.ch

Abstract

Objectives: Since 2018, the World Health Organization has recommended dolutegravir (DTG)-containing antiretroviral therapy (ART) for most people living with HIV. Country programmes across Africa have subsequently transitioned from other, mostly nonnucleoside reverse transcriptase inhibitor (NNRTI)-based ART to DTG-based ART. This study aims to assess the virological impact of programmatic transitioning to DTG-based ART in Lesotho.

Methods: The prospective Dolutegravir in Real-Life in Lesotho (DO-REAL) cohort enrols people living with HIV initiating or transitioning to DTG-based ART in Lesotho. Here, we present data from participants who transitioned from NNRTI- to DTG-based ART between February and December 2020. Blood samples collected at transition and at 16 weeks' follow-up (window 8–32 weeks) were used for viral load (VL) and resistance testing.

Results: Among 1347 participants, follow-up data was available for 1225. The majority (60%) were female, median age at transition was 47 years [interquartile range (IQR): 38–56], and median (IQR) time since ART initiation was 5.9 (3.5–9.0) years. Among those with complete VL data, the rate of viral suppression to < 100 copies/mL was 1093/1116 (98%) before, 1073/1116 (96%) at, and 1098/1116 (98%) after transition. Even among those with a VL ≥ 100 copies/mL at transition, 42/44 (95%) achieved suppression to < 100 copies/mL at follow-up. Seven participants had a VL ≥ 1000 copies/mL at follow-up and did not harbour any integrase mutations associated with resistance to DTG.

Conclusions: The high levels of viral suppression observed are encouraging regarding virological outcomes upon programmatic transitioning from NNRTI- to DTG-based ART.

INTRODUCTION

Antiretroviral therapy (ART) containing dolutegravir (DTG) is recommended as the preferred regimen type of most people living with HIV [1,2]. DTG-based ART leads to superior [3–5] or non-inferior [6–9] virological outcomes and faster viral suppression [3,4,7] compared with commonly available NNRTI-based regimens, has a high barrier to development of drug resistance [3,10], and a favourable tolerability profile [3]. For these reasons, countries including Lesotho are recommending DTG-containing regimens not only for people newly diagnosed with HIV, but also for people transitioning from other, mostly nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens to DTG-containing ART [11].

While DTG-containing ART has good virological outcomes when used in triple and dual drug regimens [3–10,12,13], DTG monotherapy is associated with the development of drug resistance and treatment failure [10], and should therefore be restricted to special circumstances [14]. This has caused concerns that DTG functional monotherapy among ART-experienced people – which could occur through just substituting the NNRTI for DTG in the case of viral resistance to the other two drugs in a three-drug regimen – might likewise adversely impact treatment outcomes [10,15]. Moreover, instances of mutations associated with resistance to DTG have been described in randomized trials even in the context of triple therapy in people with and without prior exposure to first-generation integrase strand transfer inhibitors (INSTIs) [10,16].

Consequently, there is uncertainty regarding the optimal modality for the roll-out of DTG, with open questions including the requirement for previous viral suppression, the viral load (VL) threshold allowing for transition, and the timing of VL measurement before transition. This study aims to assess virological outcomes upon programmatic transitioning from NNRTI- to DTG-based ART in a routine care setting in Lesotho, southern Africa.

MATERIALS AND METHODS

The prospective, registered Dolutegravir in Real Life in Lesotho (DO-REAL) cohort study enrolled people living with HIV initiating or transitioning to a DTG-containing ART regimen at two hospitals in Butha-Buthe district, Lesotho; for logistical reasons, one hospital was dropped after enrolling only seven participants.

According to the Lesotho guidelines, patients with a routine VL < 1000 copies/mL were to be transitioned to a first-line DTG-containing regimen typically maintaining the same nucleoside reverse transcriptase inhibitor (NRTI) backbone, whereas patients with two consecutive VLs ≥ 1000 copies/mL with enhanced adherence counselling before the follow-up measurement were to be transitioned to a second-line DTG-containing regimen with an altered NRTI backbone. With regard to the safety signal indicating an increased risk of neural tube defects in the context of DTG taken around the time of contraception [17], which has since been corrected downwards [18], Lesotho guidelines recommend an approach based on informed choice for female adolescents and women of childbearing potential [11].

In this analysis, we only include participants who transitioned from NNRTI- to DTG-containing first- or second-line ART in the ART clinic at Butha-Buthe Government Hospital in Lesotho between 10 February 2020 and 31 December 2020. Data were closed for analysis on 5 May 2021. Participants were enrolled into the study on the day of transition and had a follow-up study visit 16 weeks (window: 8–32 weeks) thereafter. Study participants received routine services, with the exception of participant interviews and the collection of a non-routine blood sample at both time points. Samples were transferred to the hospital laboratory for VL testing with a detection limit of 20 copies/mL (cobas® 4800 system; F. Hoffman-La Roche AG, Basel, Switzerland) and stored at −80°C. Resistance testing was performed at the Molecular Virology laboratory, Department of Biomedicine, University of Basel in Basel, Switzerland (RNA extraction, cDNA conversion and amplification) and at SEQ-IT GmbH & Co. KG in Kaiserslautern, Germany (deep sequencing with Illumina MiSeq platform; Illumina Inc., San Diego, CA, USA). Variants occurring with a nucleotide frequency ≥ 10% were considered during analysis. Sequences were uploaded to the Stanford HIV Drug Resistance Database (v.9.0) to assess the presence of resistance-associated mutations. Patient data were retrieved from medical records and participant interviews, and collected in the established secured database of an ongoing open cohort study in Lesotho [19], which also contains participants' prior routine VL results.

The pill count was calculated as a measure of adherence, and was calculated as follows:

$$\text{Pill count} = \frac{\text{number of pills dispensed} - \text{number of pills returned}}{\text{number of pills to be taken per day} \times \text{number of days since dispensing}} \times 100\,\%.$$

A pill count of 95–100% is considered as good adherence.

Results are summarized as frequencies and percentages for categorical variables, and medians and interquartile ranges (IQRs) for continuous variables. All analyses were done using Stata/MP v.16.1.

All participants received study information in Sesotho and gave written informed consent. In the case of illiteracy, consent was given by thumbprint and a witness signature was required. DO-REAL, as well as the open cohort study in which it is nested [19], were approved by the National Health Research Ethics Committee of Lesotho (ID134-2016). The prospective DO-REAL cohort was registered with ClinicalTrials.gov on 23 January 2020 (NCT04238767).

RESULTS

Among 1347 individuals transitioning from NNRTI- to DTG-containing ART who were enrolled to the cohort and meet the criteria for this analysis, 16-week follow-up data were available for 1225 (91%) by data closure. Of the remaining 122, 99 remained in care (68 at the same hospital but with no follow-up data collected within the window, 20 at the same hospital but withdrew from the study, 11 transferred out); 22 were recorded as lost to follow-up; and one died (this participant had a VL < 20 copies/mL both before and at transition). According to routine data, the 1225 enrolled and with follow-up data represent > 70% of eligible patients at the clinic.

Table 1 shows characteristics of participants who attended a 16-week follow-up visit (we did not observe any differences in baseline characteristics between participants with vs. those without a follow-up visit within the window period; data not shown). The majority were female, median (IQR) age at transition to DTG was 47 (38–56) years, and median time since ART initiation was 5.9 (3.5–9.0) years. The median time between receiving a previous VL and transitioning to DTG was 16 (12–24) weeks. The vast majority (98%) transitioned from efavirenz (EFV)-containing ART, with only 2% transitioning from nevirapine (NVP)-containing ART. Nine participants (1%) transitioned to second-line ART as a consequence of treatment failure, whereas all others were considered to have transitioned within first-line ART. Both before and after transition, the backbone consisted of lamivudine (3TC)/tenofovir disoproxil fumarate (TDF) for > 93% of participants. Adherence was higher in women than men, especially at transition (Table 1).

A routine VL result from before transition, a VL at transition, and a VL at follow-up were available for 1217/1225 (99%), 1174/1225 (96%) and 1166/1225 (95%) participants, respectively. Data on VL were available at all three time points for 1116/1225 (91%) participants. Figure 1 shows

TABLE 1 Participant characteristics and adherence among participants who attended a follow-up visit

N = 1225	At transition to DTG	At follow-up
Baseline characteristics		
Female	731 (60%)	
Age (years)	47 (38–56)	
Time taking ART (years)	5.9 (3.5–9.0)	
Time since HIV diagnosis (years)	7.1 (3.9–10.6)	
Time since last viral load[a] (weeks)	16 (12–24)	
ART immediately before transition		
ABC/3TC/EFV	28 (2%)	
AZT/3TC/EFV	37 (3%)	
TDF/3TC/EFV	1135 (93%)	
ABC/3TC/NVP	1 (0.1%)	
AZT/3TC/NVP	13 (1%)	
TDF/3TC/NVP	11 (1%)	
ART immediately after transition		
ABC/3TC/DTG	41 (3%)	
AZT/3TC/DTG	10 (1%)	
TDF/3TC/DTG	1174 (96%)	
Transition type		
Programmatic transition within first-line ART	1216 (99%)	
Switch to second-line ART due to treatment failure	9 (1%)	
Backbone changed at transition	71 (6%)	
Adherence		
Good adherence defined as pill count 95–100%[b]	967 (82%)	882 (90%)
Among women (N = 731)	607 (85%)	527 (91%)
Among men (N = 494)	360 (76%)	355 (89%)
ART missed on two or more consecutive days in past month[c]	98 (8%)	80 (7%)
Among women (N = 731)	44 (6%)	41 (6%)
Among men (N = 494)	54 (11%)	39 (8%)
Viral load category		
Overall[d]	N = 1174	N = 1166
< 20 copies/mL	1029 (88%)	1053 (90%)
20–99 copies/mL	98 (8%)	94 (8%)
100–999 copies/mL	25 (2%)	12 (1%)
≥ 1000 copies/mL	22 (2%)	7 (1%)
Overall, among women[e]	N = 696	N = 698

(Continues)

TABLE 1 (Continued)

N = 1225	At transition to DTG	At follow-up
< 20 copies/mL	620 (89%)	640 (92%)
20–99 copies/mL	52 (7%)	48 (7%)
100–999 copies/mL	14 (2%)	5 (1%)
≥ 1000 copies/mL	10 (1%)	5 (1%)
Overall, among men[f]	N = 478	N = 468
< 20 copies/mL	409 (86%)	413 (88%)
20–99 copies/mL	46 (10%)	46 (10%)
100–999 copies/mL	11 (2%)	7 (2%)
≥ 1000 copies/mL	12 (3%)	2 (0.4%)
If VL at transition < 20 copies/mL[g]		N = 987
< 20 copies/mL		912 (92%)
20–99 copies/mL		62 (6%)
100–999 copies/mL		8 (1%)
≥ 1000 copies/mL		5 (1%)
If VL at transition 20–99 copies/mL[g]		N = 93
< 20 copies/mL		70 (75%)
20–99 copies/mL		20 (22%)
100–999 copies/mL		3 (3%)
≥ 1000 copies/mL		0
If VL at transition 100–999 copies/mL[g]		N = 24
< 20 copies/mL		20 (83%)
20–99 copies/mL		3 (13%)
100–999 copies/mL		1 (4%)
≥ 1000 copies/mL		0
If VL at transition ≥ 1000 copies/mL[g]		N = 20
< 20 copies/mL		14 (70%)
20–99 copies/mL		5 (25%)
100–999 copies/mL		0
≥ 1000 copies/mL		1 (5%)

Note: For continuous variables, brackets indicate the interquartile range.

Abbreviations: 3TC, lamivudine; ABC, abavacir; AZT, azidothymidine; DTG, dolutegravir; EFV, efavirenz; NVP, nevirapine; TDF, tenofovir disoproxil fumarate.

[a]Missing for 10 participants.

[b]Missing for 41 participants (21 female, 20 male) at transition and 248 (155 female, 93 male) at follow-up.

[c]Self-reported; missing for three participants (all female) at transition.

[d]Missing for 51 participants at transition to DTG and 59 participants at follow-up.

[e]Missing for 35 participants at transition to DTG and 33 participants at follow-up.

[f]Missing for 16 participants at transition to DTG and 26 at follow-up.

[g]VL missing at transition to DTG and/or at follow-up for 101 participants.

the VL dynamics between these three time points (categories: < 20, 20–99, 100–999 and ≥ 1000 copies/mL). Table 1 shows the VL category at follow-up stratified by VL category at transition to DTG . At all assessed VL categories at transition, ≥ 94% of participants had a VL < 100 copies/mL at follow-up and ≥ 68% of participants had a VL < 20 copies/mL at follow-up.

Among all participants with VL data at follow-up, 19/1166 (2%) had a follow-up VL ≥ 100 copies/mL including 7/1166 (1%) with a follow-up VL ≥ 1000 copies/mL. Among those with a follow-up VL ≥ 100 copies/mL, 17/19 had a VL < 100 copies/mL at or before transition and remained on an unchanged NRTI backbone, and 2/19 had a VL ≥ 100 copies/mL at transition (544 and 22 000 copies/mL) and had an NRTI backbone change at transition to DTG. Sequencing of the sample taken at transition (544 copies/mL: not sequenced; 22 000 copies/mL: reverse transcriptase sequenced) and/or follow-up sample (271 and 17 900 copies/mL; reverse transcriptase and integrase regions sequenced for both) identified a K103N mutation conferring resistance to EFV and NVP for one participant, and no mutations associated with NRTI or INSTI resistance were detected. Of the seven with a follow-up VL ≥ 1000 copies/mL, none harboured any mutations associated with DTG resistance in the integrase region; sequencing of the reverse transcriptase region was successful for four samples and no resistance-associated mutations were detected.

DISCUSSION

In order to assess virological outcomes within programmatic transitioning to DTG-based ART, this prospective cohort study assessed virological outcomes among people routinely changing from NNRTI- to DTG-based ART in a government hospital setting in Lesotho.

The vast majority of participants, including those with viraemia at transition, achieved viral suppression by follow-up. Furthermore, viraemia detected at follow-up was unlikely to be caused by drug resistance: among 19 participants with viraemia ≥ 100 copies/mL at follow-up, only two had viraemia ≥ 100 copies/mL at transition and neither harboured NRTI resistance (assessed at transition and/or follow-up); furthermore, among seven with viraemia ≥ 1000 copies/mL at follow-up, none harboured any resistance-associated mutations in the integrase region, suggesting suboptimal adherence as the cause of viraemia. These results support the virological effectiveness of pragmatic transitioning taking into account the patient's most recent available data.

FIGURE 1 Viral load (VL) dynamics. The VL of the last measurement pre-transition from an nonnucleoside reverse transcriptase inhibitor (NNRTI)- to a dolutegravir (DTG)-based antiretroviral therapy (ART), the VL at transition, and the VL at follow-up are shown among participants with VL data at all three time points ($N = 1116$). The median time between the last VL before transition and transition to DTG was 16 weeks [interquartile range (IQR): 12–24; range: 1–191]; the median time between transition and follow-up was 16 (IQR: 16–18; range: 8–32). The colours of the nodes indicate the VL category at that time point; colour coding of the flows corresponds to the respective participant's VL pre-transition [Colour figure can be viewed at wileyonlinelibrary.com]

This study has several limitations. First, 122 participants had no follow-up data and a further 59 had no follow-up VL. While the majority of these remained in care, their 16-week virological status is unknown. Second, it is not yet certain whether the viral suppression observed during this short-term follow-up will remain stable over time. Third, the median time between the most recent VL before transition and the transition to DTG was only 16 weeks in this cohort. A longer time-frame between the previous VL test and transition would probably increase the proportion of participants with viraemia and, subsequently, NRTI resistance at transition, with unclear implications on viral suppression after transition to DTG. Fourth, the high rate of viral suppression at transition in this study limits its capacity to assess the impact of NRTI backbone resistance on viral suppression after transition to DTG-based ART. Given the high rate of viral suppression at transition in this cohort – with > 96% having a VL < 100 copies/mL – caution is advised in extrapolating these results to populations with higher rates of viraemia or with a greater time differential between the last available VL and the time of transition to

DTG. Further studies as well as longer-term follow-up are needed to assess the short- and long-term efficacy of DTG in the context of NRTI resistance and functional monotherapy. The major strength of this study is that it included > 70% of patients transitioned in this clinic and was conducted in a routine healthcare setting with minimal intervention of the study on clinical procedures and clinical decision-making. Its representativeness is supported by the fact that the rates of viral suppression observed among people in care are in line with the national average of 97% [20].

Overall, these results are encouraging regarding the short-term virological effectiveness of programmatic transitioning from NNRTI- to DTG-based ART.

ACKNOWLEDGEMENTS

notably Reitumetse Peea, Kelebone Moqethei, Katleho Tlali and Motseki Malikalike. Furthermore, we thank Ulrike Seeburg, Alexander Thielen and Martin Däumer for resistance testing, and Tracy Glass for her role in the open cohort study in which this project is nested. Lastly, we thank the study participants for taking part in this research. Open Access Funding provided by Universitat Basel.

CONFLICTS OF INTEREST
TK reports advisory board membership fees from ViiV and Gilead for work outside of this study. NDL reports having received travel grants to attend IAS, AIDS and CROI conferences from Gilead Sciences Sarl. All other authors declare that they have no competing interests.

AUTHOR CONTRIBUTIONS
NDL conceptualized this study. JAB and NDL designed the study with key input from BLN, AA, NT, JM and TK. BLN managed the study on site and oversaw all on-site procedures including consenting, data collection and on-site data cleaning. KM and IR conducted consenting procedures (together with Reitumetse Peea and Kelebone Moqethei, mentioned above) and collected data from medical records; KM, BLN and Reitumetse Peea collected blood samples. JAB conducted off-site data cleaning and analysed the data. LU performed resistance testing. JAB and NDL wrote the first version of the manuscript. All authors provided feedback on the manuscript and approved the final version.

REFERENCES
1. World Health Organization. *Interim guidelines: updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV*. Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. [Internet]. World Health Organization; 2018. Accessed May 28, 2021. https://www.who.int/publications/i/item/WHO-CDS-HIV-18.51
2. World Health Organization. *Policy brief. Update of recommendations on first- and second-line antiretroviral regimens* [Internet]. World Health Organization; 2019. Accessed May 28, 2021. https://apps.who.int/iris/handle/10665/325892
3. Kanters S, Vitoria M, Zoratti M, et al. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis. *EClinicalMedicine*. 2020;28:100573.
4. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. *N Engl J Med*. 2013;369(19):1807-1818.
5. Walmsley S, Baumgarten A, Berenguer J, et al. Brief report: dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial. [Erratum appears in J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):e33]. *J Acquir Immune Defic Syndr*. 2015;70(5):515-519.

6. NAMSAL ANRS 12313 Study Group, Kouanfack C, Mpoudi-Etame M, et al. Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1. *N Engl J Med*. 2019;381(9):816-826.
7. Calmy A, Tovar Sanchez T, Kouanfack C, et al. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon. *Lancet HIV*. 2020;7(10):e677-e687.
8. Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. *N Engl J Med*. 2019;381(9):803-815.
9. Venter WDF, Sokhela S, Simmons B, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. *Lancet HIV*. 2020;7(10):e666-e676.
10. Rhee S-Y, Grant PM, Tzou PL, et al. A systematic review of the genetic mechanisms of dolutegravir resistance. *J Antimicrob Chemother*. 2019;74(11):3135-3149.
11. Ministry of Health, Government of Lesotho. *Addendum to the national guidelines on the use of antiretroviral therapy for HIV prevention and treatment*. Ministry of Health, Government of Lesotho; 2019.
12. Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. [Erratum appears in Lancet. 2019 Jan 12;393(10167):132.]. *Lancet*. 2019;393(10167):143-155.
13. Sculier D, Wandeler G, Yerly S, et al. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial. *PLoS Med*. 2020;17(11):e1003421.
14. Braun DL, Turk T, Tschumi F, et al. Noninferiority of simplified dolutegravir monotherapy compared to continued combination antiretroviral therapy that was initiated during primary human immunodeficiency virus infection: a randomized, controlled, multisite, open-label, noninferiority trial. *Clin Infect Dis*. 2019;69:1489-1497.
15. Inzaule SC, Hamers RL, Doherty M, Shafer RW, Bertagnolio S, Rinke de Wit TF. Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens. *Lancet Infect Dis*. 2019;19(7):e246-e252.
16. Paton N, Musaazi J, Kityo CM, et al. Nucleosides and darunavir/dolutegravir in Africa (NADIA) trial: 48 wks primary outcome. In: *28th virtual conference on retroviruses and opportunistic infections (CROI)*; 2021. Accessed June 4, 2021. http://www.croiwebcasts.org/p/2021croi/croi/94
17. Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. *N Engl J Med*. 2018;379(10):979-981.
18. Zash R, Holmes L & Diseko M et al. Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana. 23rd International AIDS Conference, virtual, 6–10

July 2020 [Internet]. 2020. Accessed August 25, 2021. https://www.natap.org/2020/IAC/IAC_112.htm

19. Glass TR, Motaboli L, Nsakala B, et al. The viral load monitoring cascade in a resource-limited setting: a prospective multicentre cohort study after introduction of routine viral load monitoring in rural Lesotho. *PLoS One*. 2019;14(8):e0220337.

20. UNAIDS. *Confronting inequalities: lessons for pandemic responses from 40 years of AIDS* [Internet]. UNAIDS; 2021. (Global AIDS update 2021). Accessed August 4, 2021. https://www.unaids.org/sites/default/files/media_asset/2021-global-aids-update_en.pdf.